TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

NCT00540449 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

694

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
HIV-1
Human Immunodeficiency Virus Type 1

Interventions

DRUG: TMC278
DRUG: Efavirenz

Sponsor

Tibotec Pharmaceuticals, Ireland